Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study

• Published in: Journal of clinical and experimental hepatology Vol. 11; no. 2; pp. 227 - 231
• Main Authors: Dar, Gulzar A., Yattoo, Ghulam N., Gulzar, Ghulam M., Sodhi, Jaswinder S., Gorka, Suresh, Laway, Mushtaq A.
• Format: Journal Article
• Language: English
• Published: India Elsevier B.V 01-03-2021; Elsevier
• Subjects: genotype 3; HCV; ledipasvir; Original; SVR; ledipasvir; RNA; G; HCV; LED; SOF; genotype 3; SVR; RVR; HCV, Hepatitis C Virus; RVR, Rapid Virologic Response; SVR, Sustained Virologic Response; SOF, Sofosbuvir; LED, Ledipasvir; RNA, Ribonucleic Acid; G, Genotype
• ISSN: 0973-6883; 2213-3453
• DOI: 10.1016/j.jceh.2020.06.011

Sofosbuvir/ledipasvir (SOF/LED) is recommended for treatment of genotypes 1, 4, 5 and 6. Despite some preliminary data from the ELECTRON-2 trial regarding use of SOF/LED combination in chronic hepatitis C genotype 3, there are no guidelines recommending this combination in such patients. We conducted this study to evaluate the efficacy of the overall sustained virologic response at 12 weeks (SVR 12) and safety of SOF/LED in chronic hepatitis C genotype 3 infection in our population.
It was a prospective, hospital-based observational study. All patients with chronic hepatitis C genotype 3 treated with SOF/LED were divided into two groups: patients with cirrhosis and without cirrhosis. Patients without cirrhosis received SOF/LED (90/400 mg) for 12 weeks; however, patients with cirrhosis received treatment for 24 weeks.
We enrolled 104 patients with chronic hepatitis C over a period of 24 months. Of the total, 66 were women (63.5%) and 38 were men (36.5%). The average age was 40 years (range: 18–76 years). Of 104 patients, 86 (82.7%) were of genotype 3, 15 (14.9%) were of genotype 1 and 3 (2.9%) were of genotype 4. Ninety-two (88%) were noncirrhotic and 12 (11.5%) were cirrhotic. Ninety-five (95.2%) were treatment naïve. Among genotype 1 and 4, all patients achieved rapid virologic response and SVR 12. Of 86 genotype 3 patients, 78 (90.6%) were noncirrhotic and 8 (9.3%) were cirrhotic. Among genotype 3 patients without cirrhosis, 75 (96%) achieved SVR 12 while 6 (75%) with cirrhosis achieved SVR 12. All patients tolerated the combination well; however, some patients experienced nausea (26%), headache (25%) and fatigue (21%). No patient had to discontinue therapy due to adverse drug reactions.
Single tablet LED and SOF combination is safe and effective in genotype 3 patients without cirrhosis even without ribavirin. Being effective in genotype 3, the combination can be used as a pangenotypic drug in patients without cirrhosis.